Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pharmaceuticals Retain Potential to Cause Damage in Aquatic Environments

By University of Plymouth | October 13, 2016

More sophisticated methods may be required to assess the accumulation and wider impact of human and veterinary pharmaceuticals within the aquatic environment, scientists have said.

It comes after research led by the University of Plymouth showed that commonly used medications were not absorbed by riverine bacteria as might have been expected based on models and previous tests.

It means that many medicines of similar type, excreted into surface waters directly or via treated and untreated wastewaters and biosolids, may remain intact for a considerable time, maintaining the potential for them to cause negative impacts on aquatic organisms.

The study, funded by the Natural Environment Research Council and published in Environmental Chemistry Letters, was led by Dr. Mark Fitzsimons and Dr. Alan Tappin, of Plymouth’s Biogeochemistry Research Centre, in conjunction with the Institute of Integrative Biology at the University of Liverpool.

Fitzsimons, the corresponding author on the study, said: “The contamination of surface waters by pharmaceuticals is now widespread, but there are few data on their environmental behavior. However, recent research has suggested that the behavior of freshwater fish can be altered by current measured levels of pharmaceuticals. This study shows that improved predictive power, with respect to modelling bioaccumulation, may be needed to robustly assess the environmental risks of pharmaceuticals in aquatic environments.”

The study investigated the persistence of four widely-used, cationic pharmaceuticals included in the World Health Organization List of Essential Medicines. They included the anti-malarial drugs chloroquine and quinine, the anti-psychosis drug fluphenazine and an anti-worming agent, levamisole.

Over the course of 21 days, riverine bacteria contained with water collected from the River Tamar were exposed to each of the four pharmaceuticals, with the concentrations measured at the beginning and end of each period. Levamisole was the only pharmaceutical to be taken up by bacteria (with up to 19 % removal), while the concentrations of quinine, chloroquine and fluphenazine were unaffected.

Previous research at the University of Plymouth has suggested the natural photo degradation of diazepam and similar medicines—followed by bacterial breakdown—may reduce their potentially harmful impact on the UK’s freshwater environment.

Tappin added: “Although studies of pharmaceuticals in surface waters of high income countries is now in its fourth decade, there remains little systematic understanding of pharmaceutical transport, fate and impact. This is all the more concerning for lower income countries, where pharmaceutical use is forecast to increase significantly in the foreseeable future, with attendant increased losses of pharmaceuticals to the environment, and losses in many cases fueled by the aspiration for the increased use of waste water for the irrigation of agricultural and horticultural crops. This will only enhance the widespread diffuse contamination of aquatic systems by pharmaceuticals, with potential unforeseen consequences.”

To view the full press release, click here. 

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE